ArticleCancer immunology, immunotherapy : CII2021

Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.

Xiangyu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.